title: Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target.
abstract: Iron deficiency is known to be common and detrimental in chronic left heart failure, where parenteral iron treatment has been shown to improve exercise capacity, New York Heart Association functional class and patient wellbeing. There is now increasing interest in the role of iron in the natural history of pulmonary arterial hypertension (PAH). Iron availability influences the pulmonary vasoconstrictor response to hypoxia and accumulating evidence indicates that iron deficiency is prevalent in idiopathic and heritable forms of PAH, iron status being related to exercise capacity, symptoms and poorer survival in patients with idiopathic PAH (IPAH). Potential mechanisms behind iron deficiency in IPAH include inhibition of dietary iron uptake by the master iron regulator hepcidin. High hepcidin levels underlie the anaemia of chronic disease. Possible stimuli of the observed high levels of hepcidin in IPAH include dysfunctional bone morphogenetic protein receptor type II signalling and inflammation. Iron status may influence outcomes through modulation of the pulmonary circulation as well as myocardial and skeletal muscle function. Two parallel studies, from our centre (Hammersmith Hospital, London, UK) and others in the UK and Amsterdam (the Netherlands), investigating the safety and potential benefit of iron supplementation in patients with PAH are currently under way.
authors.affiliation: Respiratory Research Group, Faculty of Pharmacy, University of Sydney, Sydney, Australia.
authors.forename: C J
authors.initials: CJ
authors.lastname: Rhodes
authors.forename: J
authors.initials: J
authors.lastname: Wharton
authors.forename: L
authors.initials: L
authors.lastname: Howard
authors.forename: J S R
authors.initials: JS
authors.lastname: Gibbs
authors.forename: A
authors.initials: A
authors.lastname: Vonk-Noordegraaf
authors.forename: M R
authors.initials: MR
authors.lastname: Wilkins
mesh_terms: D000818:Animals; D002908:Chronic Disease; D065627:Familial Primary Pulmonary Hypertension; D005260:Female; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D000860:Hypoxia / Q000188:drug therapy / Q000503:physiopathology; D007501:Iron / Q000627:therapeutic use*; D000090463:Iron Deficiencies; D008168:Lung / Q000098:blood supply / Q000187:drug effects; D008297:Male; D051379:Mice; D051381:Rats
chemical_list: D007501:Iron